Genomic mutations and histopathologic biomarkers in Y90 radioembolization for chemorefractory colorectal liver metastases.
Conclusions: Mutational status and histopathologic grade may predict survival after Y-90 radioembolization therapy for CRLM.
PMID: 30197760 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research